Provided by Tiger Trade Technology Pte. Ltd.

Design Therapeutics, Inc.

9.77
-0.0500-0.51%
Post-market: 9.770.00000.00%19:14 EST
Volume:296.56K
Turnover:2.98M
Market Cap:556.54M
PE:-8.23
High:10.31
Open:9.89
Low:9.69
Close:9.82
52wk High:10.31
52wk Low:2.60
Shares:56.96M
Float Shares:26.28M
Volume Ratio:0.77
T/O Rate:1.13%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-1.1872
EPS(LYR):-0.8763
ROE:-29.83%
ROA:-20.49%
PB:2.79
PE(LYR):-11.15

Loading ...

Design Therapeutics Shares Rise After Leerink Upgrade

MT Newswires Live
·
Dec 04

Design Therapeutics Raised to Outperform From Market Perform by Leerink Partners

Dow Jones
·
Dec 03

Leerink Upgrades Design Therapeutics to Outperform From Market Perform, Adjusts PT to $14 From $7

MT Newswires Live
·
Dec 03

Design Therapeutics to Participate in Upcoming Investor Conferences

GlobeNewswire
·
Nov 26

Companies Like Design Therapeutics (NASDAQ:DSGN) Are In A Position To Invest In Growth

Simply Wall St.
·
Nov 26

Design Therapeutics' Friedreich Ataxia Program Shows Potential, RBC Says

MT Newswires Live
·
Nov 21

Design Therapeutics Raised to Outperform From Sector Perform by RBC Capital

Dow Jones
·
Nov 20

Design Therapeutics Inc : RBC Raises to Outperform From Sector Perform; Raises Target Price to $13 From $6

THOMSON REUTERS
·
Nov 20

Design Therapeutics upgraded to Outperform from Sector Perform at RBC Capital

TIPRANKS
·
Nov 20

U.S. RESEARCH ROUNDUP-Blackline, Carmax, Expedia

Reuters
·
Nov 07

Design Therapeutics Inc : Leerink Partners Raises Target Price to $7 From $5

THOMSON REUTERS
·
Nov 07

Analysts Conflicted on These Healthcare Names: Design Therapeutics (DSGN) and Siemens Healthineers AG (OtherSEMHF)

TIPRANKS
·
Nov 07

RBC Capital Sticks to Its Hold Rating for Design Therapeutics (DSGN)

TIPRANKS
·
Nov 07

Design Therapeutics Is Maintained at Sector Perform by RBC Capital

Dow Jones
·
Nov 06

RBC Raises Price Target on Design Therapeutics to $6 From $5, Keeps Sector Perform, Speculative Risk

MT Newswires Live
·
Nov 06

U.S. RESEARCH ROUNDUP-Acadia Pharmaceuticals, Applovin, Centuri Holdings

Reuters
·
Nov 06

Design Therapeutics Inc : RBC Raises Target Price to $6 From $5

THOMSON REUTERS
·
Nov 06

Design Therapeutics reports Q3 EPS (30c), consensus (34c)

TIPRANKS
·
Nov 06

Design Therapeutics Q3 EPS $(0.30) Beats $(0.34) Estimate

Benzinga
·
Nov 06

Design Therapeutics Reports Third Quarter Net Loss of $17 Million

Reuters
·
Nov 06